Divestitures (Details) $ in Millions			3 Months Ended		12 Months Ended
	Oct. 01, 2023 USD ($) product	Nov. 29, 2022 USD ($)	Dec. 31, 2023 USD ($) product	Dec. 31, 2022 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($) product	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets and subsidiaries						$ 364.1	$ 1,950.0	$ 96.7
Impairment of goodwill						$ 581.0	117.0	0.0
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]						Other Nonoperating Income (Expense)
Number of insulin analog products | product			3			3
Other Nonoperating Income (Expense)						$ 9.8	1,790.7	5.8
Loss (gain) on disposal of business						(239.9)	1,754.1	0.0
Biocon Biologics
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Equity Securities, FV-NI, Gain (Loss)						(21.1)
Product rights and licenses
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of intangible assets				$ 172.9		32.0	172.9	$ 83.4
Biocon Biologics
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Other Nonoperating Income (Expense)						168.0	17.7
Biocon Biologics | Scenario, Forecast | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Deferred cash consideration					$ 335.0
Disposal Group, Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets and subsidiaries	$ 1,400.0
Number Of Women's Healthcare Products Sold | product	2
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Biocon Biologics
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration received on divestiture		$ 3,000.0
Proceeds from sale of assets and subsidiaries		2,000.0
Equity consideration		$ 1,000.0
Ownership percentage		12.90%
Contingent liability (up to)		$ 250.0
Gain on divestiture of business		$ 1,750.0
Disposal Group, Including Discontinued Operations, Contingent Consideration Paid						220.0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | OTC Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets and subsidiaries	$ 2,170.0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Women's Health Products
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss (gain) on disposal of business						156.2
Disposal Group, Held-for-sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Property, plant and equipment, net			$ 262.2	0.0		262.2	$ 0.0
Disposal Group, Held-for-sale, Not Discontinued Operations | Upjohn Distributor Markets
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on divestiture of business						85.2
Total impairment charge			136.4	374.2
Disposal Group, Held-for-sale, Not Discontinued Operations | Upjohn Distributor Markets | Inventories
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total impairment charge				84.3
Disposal Group, Held-for-sale, Not Discontinued Operations | Upjohn Distributor Markets | Emerging Markets
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of goodwill				117.0		7.0
Disposal Group, Held-for-sale, Not Discontinued Operations | OTC Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total impairment charge			734.7
Impairment of goodwill			$ 580.1			$ 580.1
Write down-to fair value, less costs to sell				$ 154.7